Despite a lack of validation in xenograft models and patients, the initial gene-related drug screening on CRC organoids shows that KRAS mutant organoids and KRAS wild-type/BRAF mutant organoids were insensitive to cetuximab, which were consistent with the response of targeted clinical therapy [68, 84]. This evidence concerns the gene BRAF and colorectal carcinoma.